News
Roche places a $1bn bet on C4T degrader-antibody conjugates
Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.
Oncology
LSX2026: Addressing adult eye cancer, with Roi Raz
Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
News
Syneron raises $150m for macrocyclics, and other financings
Our round-up of recent biotech venture capital financings includes nine-figure rounds for Syneron, Stipple Bio, and Sidewinder.
Oncology
From preclinical toxicology to clinical safety: The path for...
Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.
Oncology
Advancing the case for cell and gene therapies
After the Advanced Therapies Congress, Europe, pharmaphorum spoke with Resolution Therapeutics' Lara Campana and Vianautis' Dr Sam Barker.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
